Rep. Gilbert Ray Cisneros, Jr. Purchases BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in BioCryst Pharmaceuticals stock on July 10th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ:BCRX opened at $9.96 on Tuesday. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The company has a 50 day moving average of $9.75 and a 200-day moving average of $9.20. The stock has a market cap of $2.55 billion, a price-to-earnings ratio of -6.64 and a beta of 0.57.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 EPS for the quarter, beating analysts’ consensus estimates of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%.The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. During the same quarter in the prior year, the company posted $0.15 earnings per share. The firm’s revenue was up 33.6% on a year-over-year basis. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -2.25 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. BlackRock Inc. bought a new stake in BioCryst Pharmaceuticals during the 2nd quarter worth about $238,930,000. RA Capital Management L.P. bought a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at about $123,452,000. Jupiter Topco LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the second quarter valued at about $95,268,000. Deerfield Management Company L.P. increased its position in shares of BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after acquiring an additional 7,477,000 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in BioCryst Pharmaceuticals by 7,807.2% during the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock worth $57,791,000 after acquiring an additional 7,310,745 shares in the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BCRX has been the subject of several research analyst reports. Cantor Fitzgerald boosted their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Royal Bank Of Canada dropped their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an “outperform” rating on the stock in a research note on Thursday, August 6th. JPMorgan Chase & Co. started coverage on BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $32.00 target price on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Finally, Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 29th. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.60.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical?stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small?molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure?based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.